Information regarding trade in Clines share, CLINE B

Cline Scientific AB (publ) ("Cline" or the "Company") have the following information regarding trade in the Company share, CLINE B.

Starting January 18th CLINE B will trade through the auction method introduced this afternoon by Nasdaq for certain stocks on Nasdaq First North Growth Market. According to Nasdaq this aims to assure a better price structure for those stocks with low liquidity and high spread, that is the difference between buy- and sell prices. For more information, please refer to information from Nasdaq via the links below,

.IT Notice 16/23

 IT - Auction Trading semi-annual periodic update (04/24)

For more information, please contact:
Patrik Sundh, CEO
Email: [e-mail]
Phone: [phone]

 

Cline Scientific AB (publ)                                                
Pepparedsleden 1
AstraZeneca BioVentureHub                                               Email: [e-mail]
431 53  MÖLNDAL                                                             Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline's unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis. 

https://news.cision.com/cline/r/information-regarding-trade-in-clines-share--cline-b,c3907672

https://mb.cision.com/Main/12114/3907672/2536289.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English